BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer  before age 50

Robert W Haile; Duncan C Thomas; Valerie McGuire; Anna Felberg; Esther M John; Roger L Milne; John L Hopper; Mark A Jenkins; A Joan Levine; Mary M Daly; Saundra S Buys; Ruby T Senie; Irene L Andrulis; Julia A Knight; Andrew K Godwin; Melissa Southey; Margaret R E McCredie; Graham G Giles; Lesley Andrews; Katherine Tucker; Alexander Miron; Carmel Apicella; Andrea Tesoriero; Anita Bane; Malcolm C Pike; kConFab Investigators; Ontario Cancer Genetics Network Investigators; Alice S Whittemore

doi:10.1158/1055-9965.EPI-06-0258

General Gynecology · Breast Health

BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50

Haile RW, Thomas DC, McGuire V, Felberg A, John EM, Milne RL, Hopper JL, Jenkins MA, Levine AJ, Daly MM, Buys SS, Senie RT, Andrulis IL, Knight JA, Godwin AK, Southey M, McCredie MR, Giles GG, Andrews L, Tucker K, Miron A, Apicella C, Tesoriero A, Bane A, Pike MC, kConFab Investigators, Ontario Cancer Genetics Network Investigators, Whittemore AS

Published October 6, 2006 Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 15(10), 1863-1870

DOI 10.1158/1055-9965.EPI-06-0258 PMID 17021353

Abstract

Background

Understanding the effect of oral contraceptives on risk of breast cancer in BRCA1 or BRCA2 mutation carriers is important because oral contraceptive use is a common, modifiable practice.

Methods

We studied 497 BRCA1 and 307 BRCA2 mutation carriers, of whom 195 and 128, respectively, had been diagnosed with breast cancer. Case-control analyses were conducted using unconditional logistic regression with adjustments for family history and familial relationships and were restricted to subjects with a reference age under 50 years.

Results

For BRCA1 mutation carriers, there was no significant association between risk of breast cancer and use of oral contraceptives for at least 1 year [odds ratio (OR), 0.77; 95% confidence interval (95% CI), 0.53-1.12] or duration of oral contraceptive use (P(trend) = 0.62). For BRCA2 mutation carriers, there was no association with use of oral contraceptives for at least 1 year (OR, 1.62; 95% CI, 0.90-2.92); however, there was an association of elevated risk with oral contraceptive use for at least 5 years (OR, 2.06; 95% CI, 1.08-3.94) and with duration of use (OR(trend) per year of use, 1.08; P = 0.008). Similar results were obtained when we considered only use of oral contraceptives that first started in 1975 or later.

Conclusions

We found no evidence overall that use of oral contraceptives for at least 1 year is associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers before age 50. For BRCA2 mutation carriers, use of oral contraceptives may be associated with an increased risk of breast cancer among women who use them for at least 5 years. Further studies reporting results separately for BRCA1 and BRCA2 mutation carriers are needed to resolve this important issue.

Topics

General Gynecology › Breast Health › Breast Cancer Risk · Contraception › Oral Contraceptives › Cancer Risk

Robert W Haile, Duncan C Thomas, Valerie McGuire, Anna Felberg, Esther M John, Roger L Milne, John L Hopper, Mark A Jenkins, A Joan Levine, Mary M Daly, Saundra S Buys, Ruby T Senie, Irene L Andrulis, Julia A Knight, Andrew K Godwin, Melissa Southey, Margaret R E McCredie, Graham G Giles, Lesley Andrews, Katherine Tucker, Alexander Miron, Carmel Apicella, Andrea Tesoriero, Anita Bane, Malcolm C Pike, Alice S Whittemore

Bob Haile, Rob Haile, Bobby Haile, R Haile, D Thomas, V McGuire, A Felberg, E John, R Milne, Jack Hopper, J Hopper, M Jenkins, M Daly, S Buys, R Senie, I Andrulis, J Knight, Andy Godwin, Drew Godwin, A Godwin, M Southey, Maggie McCredie, Peggy McCredie, M McCredie, G Giles, L Andrews, Kathy Tucker, Kate Tucker, Katie Tucker, K Tucker, Alex Miron, A Miron, C Apicella, A Tesoriero, A Bane, M Pike, A Whittemore

PMID 17021353 17021353 DOI 10.1158/1055-9965.EPI-06-0258 10.1158/1055-9965.EPI-06-0258 Haile et al. 2006, Haile 2006

Keywords

Contraceptives, Oral, Receptors, Estrogen, Receptors, Progesterone

BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50

Abstract

Topics

By this author

Related research

Keywords